Omarigliptin
- Generic Name
- Omarigliptin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20F2N4O3S
- CAS Number
- 1226781-44-7
- Unique Ingredient Identifier
- CVP59Q4JE1
- Background
Omarigliptin has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency.
- Indication
用于治疗2型糖尿病。
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4202
- Registration Number
- NCT01703208
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 213
- Registration Number
- NCT01698775
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 585
- Registration Number
- NCT01697592
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 751
- Registration Number
- NCT01682759
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 49
- Registration Number
- NCT01407276
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 685
- Registration Number
- NCT01217073
Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01088711
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath